Ponesimod (relapsing forms of multiple sclerosis (RMS))


  • Active Substance: Ponesimod
  • Name: Ponvory®
  • Therapeutic area: Multiple sclerosis
  • Pharmaceutical company: Janssen-Cilag GmbH

Time table:

  • Start: 15.06.2021
  • Final decision by G-BA: 02.12.2021

Final decision:

  • Patients who did not yet receive disease modifying therapeutics or who did receive disease modifying therapeutics but have not a highly active disease:
    - No decision on additional benefit yet. G-BA updated the comparative therapy and assigned IQWiG to assess the now relevant study. The final decision on additional benefit is due in 6 months.
  • Patients who received disease modifying therapeutics but still have a highly active disease: No additional benefit proved